AI in scientific discovery & health
Key Questions
What progress has been made on the Cambridge AI-designed super-antigen?
The Cambridge AI-designed super-antigen targets all coronaviruses and has entered first-in-human trials. This development is part of ongoing AI applications in health and scientific discovery.
How did a reasoning model solve an 80-year-old math problem?
An OpenAI reasoning model cracked the long-standing math problem, as detailed in the OpenAI Podcast Ep. 20. This highlights advances in AI reasoning capabilities relevant to scientific discovery.
What is Reid Hoffman focusing on after leaving the Microsoft board?
Reid Hoffman departed the Microsoft board to concentrate on Manus, his new AI drug discovery startup. The move aligns with broader AI efforts in health and life sciences.
What funding did Collate recently secure and for what purpose?
Collate raised a $95 million Series A round to expand its AI platform for regulated life sciences workflows. This supports AI tools in regulated scientific and health environments.
What AI research innovations were discussed at Google I/O 2026?
Google I/O 2026 covered Gemini for Science, Agentic AI, and related research innovations in an 8-minute video breakdown. These topics connect to AI's role in accelerating scientific discovery and health applications.
Cambridge AI-designed super-antigen for all coronaviruses enters first-in-human trial. Also: AutoMedBench; Mayo Clinic-Microsoft; Tempus AI; ChatGPT Health. New this batch: Reasoning model solves 80-year-old math problem. New from this reading: Evidence-based AI framework for toxicology. New from this batch: Reid Hoffman leaves Microsoft board to focus on Manus, an AI drug discovery startup.